BioLineRx (NASDAQ:BLRX) announces that its 32-patient Phase 1/2 clinical trial evaluating the safety of its celiac disease therapy candidate BL-7010 demonstrated an acceptable safety profile in both single and repeated ascending doses. Only one patient failed to complete the 14-day treatment period.
The company intends to continue its investigation of lower repeated doses of BL-7010 in order to identify the optimal dose for an efficacy study.
BL-7010 is a non-absorbable, orally-available polymer intended for the treatment of celiac disease. It has a high affinity for gliadins, the immunogenic proteins present in gluten that cause the disease. BL-7010 sequesters gliadins which masks them from enzyme degradation and prevents the formation of immunogenic peptides that trigger the immune response. BL-7010 is excreted with gliadin in the feces and not absorbed into the blood.